Mass Tort brief
Mass Tort Brief: High Court Approves Historic Talc Suit as Corporate Liability Shifts
London High Court greenlights historic J&J talc action while FTSE leaders Reckitt and AstraZeneca face critical product liability rulings.
Mass Tort
The High Court greenlit the UK's largest product action — forcing J&J to defend 7,000 talc cancer claims in London after failing to resolve US liabilities.
BackgroundThousands of plaintiffs globally allege that J&J's talc baby powder contained trace asbestos that caused mesothelioma and ovarian cancer. While J&J withdrew the product globally, it continues to fight parallel litigation across multiple jurisdictions.
- The Group Litigation Order consolidation allows over 7,000 individual UK claims to proceed collectively under unified case management in London.
- Claimants' solicitors requested expedited trial scheduling due to high terminal illness rates among elderly plaintiffs suffering from mesothelioma.
- J&J maintains its consumer talc products were safe and asbestos-free, while spinoff Kenvue remains insulated from legacy talc liabilities under separation agreements.
Mass Tort
A US federal court closed contract-law loopholes against AstraZeneca — protecting pandemic vaccine makers from statutory immunity breaches while UK High Court claims proceed.
BackgroundPharmaceutical manufacturers received statutory PREP Act protection during the COVID-19 pandemic to ensure rapid vaccine production and distribution. Plaintiffs attempted to bypass these immunity shields by framing injury claims as contractual breaches rather than personal injury torts.
- The appellate court ruled that PREP Act statutory immunity preempts both contract and product liability claims arising from pandemic countermeasure administration.
- The precedent closes a key legal loophole created when lower courts permitted contract litigation over rare vaccine adverse effects.
- AstraZeneca still faces ongoing vaccine injury litigation in the UK High Court brought under the Consumer Protection Act 1987.
Mass Tort
Reckitt Benckiser faces its first federal formula bellwether — testing multi-million dollar liabilities that directly threaten FTSE investor confidence.
BackgroundFederal multidistrict litigation consolidates hundreds of lawsuits alleging cow's milk baby formula causes necrotizing enterocolitis in premature infants. FTSE-listed Reckitt Benckiser faces potential financial exposure that has already weighed heavily on its London market valuation.
- The Inman bellwether trial in US federal court will test key causation arguments against Enfamil manufacturer Mead Johnson.
- State court juries previously returned $495m and $70m verdicts against formula makers over failure to warn of gastrointestinal risks.
- London-listed parent company Reckitt Benckiser faces investor pressure to quantify liability reserves as bellwether trials progress.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
